Skip to main content
NCBI home page
Heart logoLink to Heart
. 1998 May;79(5):497–501. doi: 10.1136/hrt.79.5.497

Distribution of fast heart rate episodes during paroxysmal atrial fibrillation

K Hnatkova 1, F Murgatroyd 1, C Alferness 1, A Camm 1, M Malik 1
PMCID: PMC1728697  PMID: 9659199

Abstract

Objective—To investigate the defibrillator waiting time (time between the recognition of atrial fibrillation and the actual shock) by studying paroxysmal atrial fibrillation episodes with RR intervals shorter than a certain limit (that is, episodes during which defibrillation should not be attempted).
Methods—Long term 24 hour Holter recordings from a digoxin v placebo crossover study in patients with paroxysmal atrial fibrillation were analysed. In all, 23 recordings with atrial fibrillation episodes of at least 1000 ventricular cycles and with < 20% Holter artefacts or noise were used (11 recorded on placebo and 12 on digoxin). For each recording, the mean ("mean waiting time") and maximum ("maximum waiting time") duration of continuous sections of atrial fibrillation episodes with all RR intervals shorter than a certain threshold were evaluated, ranging the threshold from 400 to 1000 ms in 10 ms steps. For each threshold, the mean and maximum waiting times were compared between recordings on placebo and on digoxin.
Results—Both the mean and maximum waiting times increased exponentially with increasing threshold. Practically acceptable mean waiting times less than one minute were observed with thresholds below 600 ms. There were no significant differences in mean waiting times and maximum waiting times between recordings on placebo and digoxin, and only a trend towards shorter waiting times on digoxin. 
Conclusions—Introduction of a minimum RR interval threshold required to deliver atrial defibrillation leads to practically acceptable delays between atrial fibrillation recognition and the actual shock. These delays are not prolonged by digoxin treatment.

 Keywords: atrial defibrillator;  shock delivery;  ventricular proarrhythmia;  digoxin

Full Text

The Full Text of this article is available as a PDF (121.7 KB).

Figure 1  .

Figure 1  

Open in a new tab

Mean waiting times—that is, mean durations of atrial fibrillation sections with RR intervals shorter than a given threshold (x axis). Vertical axes use a logarithmic scale in seconds, the dashed lines correspond to 1 s, 1 min, and 1 h waiting times. The mean waiting times were averaged separately in recordings made on placebo and on digoxin. The averages and standard errors used in the graphs were obtained from the mean waiting times in individual tapes rather than from individual atrial fibrillation episodes. Panel A illustrates the results from pooled data, panel B shows the results from case controlled data (see the text for details).

Figure 2  .

Figure 2  

Open in a new tab

Maximum waiting times—that is, maximum durations of atrial fibrillation sections with RR intervals shorter than a given threshold (x axis). Details and layout as in fig 1.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alt E., Schmitt C., Ammer R., Coenen M., Fotuhi P., Karch M., Blasini R. Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol. 1994 May;17(5 Pt 2):1067–1078. doi: 10.1111/j.1540-8159.1994.tb01462.x. [DOI] [PubMed] [Google Scholar]
  2. Aragam J. R., Main J., Guerrero J. L., Vlahakes G. J., Southern J. F., Adams M. S., Weyman A. E., Levine R. A. Doppler color flow mapping of epicardial coronary arteries: initial observations. J Am Coll Cardiol. 1993 Feb;21(2):478–487. doi: 10.1016/0735-1097(93)90692-t. [DOI] [PubMed] [Google Scholar]
  3. Ayers G. M., Alferness C. A., Ilina M., Wagner D. O., Sirokman W. A., Adams J. M., Griffin J. C. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation. 1994 Jan;89(1):413–422. doi: 10.1161/01.cir.89.1.413. [DOI] [PubMed] [Google Scholar]
  4. Ayers G. M., Griffin J. C. The future role of defibrillators in the management of atrial fibrillation. Curr Opin Cardiol. 1997 Jan;12(1):12–17. doi: 10.1097/00001573-199701000-00003. [DOI] [PubMed] [Google Scholar]
  5. Barold H. S., Wharton J. M. Ventricular fibrillation resulting from synchronized internal atrial defibrillation in a patient with ventricular preexcitation. J Cardiovasc Electrophysiol. 1997 Apr;8(4):436–440. doi: 10.1111/j.1540-8167.1997.tb00809.x. [DOI] [PubMed] [Google Scholar]
  6. Cook R. J. The design and analysis of randomized trials with recurrent events. Stat Med. 1995 Oct 15;14(19):2081–2098. doi: 10.1002/sim.4780141903. [DOI] [PubMed] [Google Scholar]
  7. Cooper R. A., Alferness C. A., Smith W. M., Ideker R. E. Internal cardioversion of atrial fibrillation in sheep. Circulation. 1993 May;87(5):1673–1686. doi: 10.1161/01.cir.87.5.1673. [DOI] [PubMed] [Google Scholar]
  8. Cowan J. C. Antiarrhythmic drugs in the management of atrial fibrillation. Br Heart J. 1993 Oct;70(4):304–306. doi: 10.1136/hrt.70.4.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Falk R. H., Leavitt J. I. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med. 1991 Apr 1;114(7):573–575. doi: 10.7326/0003-4819-114-7-573. [DOI] [PubMed] [Google Scholar]
  10. Galun E., Flugelman M. Y., Glickson M., Eliakim M. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest. 1991 Apr;99(4):1038–1040. doi: 10.1378/chest.99.4.1038. [DOI] [PubMed] [Google Scholar]
  11. Lau C. P., Tse H. F., Lok N. S., Lee K. L., Ho D. S., Sopher M., Murgatroyd F., Camm A. J. Initial clinical experience with an implantable human atrial defibrillator. Pacing Clin Electrophysiol. 1997 Jan;20(1 Pt 2):220–225. doi: 10.1111/j.1540-8159.1997.tb04847.x. [DOI] [PubMed] [Google Scholar]
  12. Lok N. S., Lau C. P., Ho D. S., Tang Y. W. Hemodynamic effects and clinical determinants of defibrillation threshold for transvenous atrial defibrillation using biatrial biphasic shocks in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol. 1997 Apr;20(4 Pt 1):899–908. doi: 10.1111/j.1540-8159.1997.tb05492.x. [DOI] [PubMed] [Google Scholar]
  13. McMurray J., Rankin A. Cardiology--II: Treatment of heart failure and atrial fibrillation and arrhythmias. BMJ. 1994 Dec 17;309(6969):1631–1635. doi: 10.1136/bmj.309.6969.1631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Murgatroyd F. D., Slade A. K., Sopher S. M., Rowland E., Ward D. E., Camm A. J. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol. 1995 May;25(6):1347–1353. doi: 10.1016/0735-1097(94)00555-5. [DOI] [PubMed] [Google Scholar]
  15. Murgatroyd F. D., Xie B., Copie X., Blankoff I., Camm A. J., Malik M. Identification of atrial fibrillation episodes in ambulatory electrocardiographic recordings: validation of a method for obtaining labeled R-R interval files. Pacing Clin Electrophysiol. 1995 Jun;18(6):1315–1320. doi: 10.1111/j.1540-8159.1995.tb06972.x. [DOI] [PubMed] [Google Scholar]
  16. Rawles J. M., Metcalfe M. J., Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990 Apr;63(4):225–227. doi: 10.1136/hrt.63.4.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Roberts S. A., Diaz C., Nolan P. E., Salerno D. M., Stapczynski J. S., Zbrozek A. S., Ritz E. G., Bauman J. L., Vlasses P. H. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol. 1993 Sep 1;72(7):567–573. doi: 10.1016/0002-9149(93)90353-e. [DOI] [PubMed] [Google Scholar]
  18. Rudd J. H., Maxwell S., Kendall M. The causes and management of atrial fibrillation. J Clin Pharm Ther. 1996 Feb;21(1):37–43. doi: 10.1046/j.1365-2710.1996.89475894.x. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES